(Q38979277)

8 September 2017

1 reference

title

Antibody-Based Treatment of Acute Myeloid Leukemia (English)

1 reference

8 September 2017

Phillip M Garfin

1

1 reference

8 September 2017

Eric J Feldman

series ordinal

2

1 reference

8 September 2017

publication date

12 October 2016

1 reference

Current hematologic malignancy reports

8 September 2017

published in

1 reference

8 September 2017

volume

11

1 reference

8 September 2017

issue

6

1 reference

8 September 2017

page(s)

545-552

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-016-0349-7

8 September 2017

exact match

0 references

cites work

Antibody therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

What happened to anti-CD33 therapy for acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Immune checkpoint blockade in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoieti

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Mylotarg: antibody-targeted chemotherapy comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Interleukin-3 receptor in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Targeting FLT3 to treat leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Update on rational targeted therapy in AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-016-0349-7

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

21 January 2018

1 reference

12 December 2020

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

1 reference

12 December 2020

Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates

1 reference

12 December 2020

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Differences in CD33 intensity between various myeloid neoplasms

1 reference

12 December 2020

Considerations for targeting malignant stem cells in leukemia

1 reference

12 December 2020

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

12 December 2020

Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia

1 reference

12 December 2020

Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg).

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Flow cytometry in the diagnosis of acute leukemia

1 reference

12 December 2020

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

1 reference

12 December 2020

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

12 December 2020

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

12 December 2020

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia

1 reference

12 December 2020

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia

1 reference

12 December 2020

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

1 reference

12 December 2020

10.1007/S11899-016-0349-7

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1043515422

0 references

1 reference